Shots:

• The two global companies collaborated to develop- manufacture- and distribute REGN-COV2 across the globe. The agreement is expected to increase the supply of REGN-COV2 to at least 3.5 times the current capacity with the potential for expanding it further
• Regeneron will lead the distribution in the US while Roche will be responsible for the distribution outside the US- both will bear distribution expenses in their designated territories. Each partner will dedicate a manufacturing capacity to REGN-COV2 every year while the collaborators have started the technology transfer process
• The partners will jointly fund and execute the ongoing P-III prevention and P-I healthy volunteers safety studies as well as additional global studies to assess the potential for REGN-COV2 against COVID-19. Additionally- Roche will solely responsible for the initial EMA’s approval or conducting any additional studies required for approval outside the US

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche